

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

<p>Substitute for form 1449A/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
Sheet	1	of	2	<b>Application Number</b> To Be Assigned <b>Filing Date</b> Filed Concurrently Herewith <b>First Named Inventor</b> ACHARD, et al <b>Group Art Unit</b> 1614 1624 <b>Examiner Name</b> To Be Assigned <b>Attorney Docket Number</b> USST00008US CNT1	

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	8/21/06
-----------------------	--	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/088 (10-98)

Approved for use through 10/31/99. OMB 0651-0031

**Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<u>Application Number</u>	Not Yet Assigned
				<u>Filing Date</u>	Filed Concurrently Herewith
				<u>First Named Inventor</u>	ACHARD, et al.
				<u>Group Art Unit</u>	1614-1624
				<u>Examiner Name</u>	Not Yet Assigned
				<u>Attorney Docket Number</u>	USST00008US CNT1
Sheet	2	of	2		
(use as many sheets as necessary)					

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DR</i>		*DAMASIO, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, Vol. 2, 1996, pp 1992-6	
<i>DR</i>		*LAYZER, Degenerative Diseases of the Nervous System, 20th Edition, Vol. 2, 1996, pp 2050-2057	
<i>DR</i>		*PERTWEE, Cannabinoid Receptor Ligands, Tocris Reviews, No. 16, April 2001, pp 1-8	
<i>DR</i>		*SIMONE, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, Vol. 1, 1996, pp 1004-1010	

Examiner Signature	Dwight Berg B	Date Considered	2/21/06
-----------------------	---------------	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

O I P E  
AUG 3 0 2004

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	1	Attorney Docket Number	USST00008 - US - CNT - 1
-------	---	----	---	------------------------	--------------------------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR		CONSROE et al, Potential Role of Cannabinoids for Therapy of Neurological Disorders, Marijuana / Cannabinoids Neurobiology and Neurophysiology, Murphy L. and Barthe A. Eds., CRC Press, Vol. 459, 1992, pp 459-524	
DR		DAVE, Acylative Dealkylation of N-tert-Butyl-3-substituted Azetidines: Facil Access to [1.1.0]Azabicyclobutane, 3-Hydroxyazetidinium Hydrochloride, and 3-Azetidinones, J. Org. Chem., Vol. 61, 1996, pp 5454-5455	
DR		HOLLISTER, Health Aspects of Cannabis, Pharm. Rev., Vol. 38, No. 1, 1986, pp 1-20	
DR		KATRITZKY et al, Novel Syntheses of 1,3,3-Trinitroazetidine , J. Heterocycl. Chem. Vol. 271, 31, 1994, pp 271-275	
DR		KUSTER et al, Aminoalkylindole Binding in Rat Cerebellum: Selective Displacement by Natural and Synthetic Cannabinoids, J. Pharmacol. Exp. Ther., Vol. 264, No. 3, 1993, pp 1352-1363	
DR		PERTWEE, Effects of cannabinoids on thermoregulation: a brief review, Marihuana '84 Proceedings of the Oxford Symposium on Cannabis, Harvey d. J. Eds, 1985, pp 263-277	
DR		SETH et al , Chemistry and Pharmacology of Cannabis, Progress in Drug Research, 1991, pp 71-114	

Examiner Signature

Shyamal Ray

Date Considered

21/10/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.